|

Description of the Copper Concentration in Breast Milk in Women Treated for Wilson's Disease

RECRUITINGN/ASponsored by Fondation Ophtalmologique Adolphe de Rothschild
Actively Recruiting
PhaseN/A
SponsorFondation Ophtalmologique Adolphe de Rothschild
Started2022-05-11
Est. completion2026-08
Eligibility
Age18 Years+
SexFEMALE
Healthy vol.Accepted

Summary

Wilson's disease is a rare genetic disease, affecting less than 1,500 people in France. The transmission is autosomal recessive linked to an anomaly of the ATP7B gene on chromosome.This gene codes for an ATPase-type transmembrane protein involved in the transport of copper through the cell plasma member.This gene codes for an ATPase-type transmembrane protein involved in the transport of copper through the cell plasma member. If there is no mutation, this ATPase incorporates copper into apo-ceruloplasmin to be released into the blood serum. The mutation of the ATP7B gene results in a defective biliary excretion of copper, leading to its accumulation in the liver, but also in other organs such as the eye or the brain. Advances in treatment have dramatically changed the prognosis for Wilson's disease, making the desire for pregnancy more confident. The consensus is to maintain treatment during pregnancy, reducing the dosage to limit teratogenicity as well as the risk of fetal copper deficiency.The mammary gland is the primary site of copper metabolism in lactation, and ATPase 7B is the primary effector. It has been shown in a mouse model of Wilson's disease (ATP7B - / - mouse) with treatment, that mothers accumulate copper in the liver but also in the mammary gland. However, a recent study showed that the copper level in breast milk was normal in 18 Wilsonian patients treated with D-penicillamine, trientine salts or zinc salts, suggesting that breastfeeding is possible in these patients without risk to the development of the infants.The problem of breastfeeding newborns for patients with Wilson's disease is therefore associated with a risk of copper deficiency in the newborn due to insufficiently rich breast milk in copper due to drugs. In addition, the passage into breast milk of treatments is not sufficiently known. These factors make breastfeeding not currently recommended for Wilsonian mothers,However, many patients wish to breastfeed and some of them breastfeed their newborns despite the risk of breastfeeding

Eligibility

Age: 18 Years+Sex: FEMALEHealthy volunteers accepted
Criteria for inclusion :

* Patient aged 18 years or over.
* Wilson's disease fulfilling the criteria for the Leipzig score
* Pregnancy in progress whatever the term.
* Express consent to participate in the study.
* Affiliate or beneficiary of a social security system.

Criteria for non-inclusion :

* Liver transplant patient
* No affiliation to Social Security system
* VuInability to give free and informed consent
* Patient benefiting from a legal protection measure

Conditions2

Liver DiseaseWilson's Disease

Browse More Trials

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.